Researchers synthesized 10 new derivatives of torkinib, identifying compound 4k as a potent mTOR inhibitor that kills both proliferating cancer cells and senescent cells without affecting STAT3 signaling. In contrast, analog compound 4j inhibited both mTOR and STAT3 pathways but showed different cellular effects. This represents a significant advance in targeting cellular aging mechanisms. The mTOR pathway regulates cell growth and metabolism, becoming dysregulated with age and contributing to cancer development. Senescent cells accumulate with aging and drive inflammation and tissue dysfunction. Compounds that can simultaneously clear senescent cells while inhibiting mTOR offer a dual approach to combating age-related diseases and cancer. The structure-activity relationship findings provide a roadmap for developing more potent senolytic drugs. However, this remains early-stage drug development work conducted in laboratory conditions. The selectivity of 4k for mTOR over STAT3 is particularly intriguing, as it suggests more targeted therapeutic effects with potentially fewer side effects than broad-spectrum inhibitors. Clinical translation will require extensive safety and efficacy testing.